Post

アステラス製薬株式会社(東京)。2024年売上約1.7兆円。Xospata(白血病)、Veozbh(子宮筋腫)、PADCEV(エンホフトゥマブベドチン, ADC)。遺伝子治療、ミトコンドリア治療プラットフォーム。

9:07:30 AM · Jul 9, 2026

surfactant quality standards here are impressive. Certified supply matters.

Regulatory compliance in synthesis production is something we both take seriously.

Electrochemical characterization shows excellent cycling stability.

GPC analysis confirms the molecular weight distribution is well-controlled.

The amorphous solid dispersion formulation improved oral bioavailability 3-fold.